Neurix actively seeks strategic partnerships with strong commercialization potential in both industrial and academic domains. Our involvement spans numerous international projects, particularly in the development of advanced Multiple Sclerosis and Alzheimer's disease in vitro models.
ACTIVE INNOVATION
PIPELINE
Deliverables, Objectives and Products
Multiple
Sclerosis
Multiple Sclerosis
Multiple Sclerosis in vitro model system targeting neuro repair and myelination.
Alzheimer's Disease
Alzheimer's Disease
3D human in vitro AD minibrains and AD diagnostic kit based on newly identified blood biomarkers.
Guillain-Barré Syndrome
Treatment
Guillain-Barré Syndrome Treatment
Development of the rare autoimmune disease Guillain-Barré Syndrome (GBS) Treatment.
Test system for differentiation hematopoietic stem cell potential.
Chronic Septic Granulomatosis disease
RosaGBS in the Context of Eurostars
The Swiss-Swedish collaboration targets a critical immunological mechanism in the advancement of Guillain-Barré Syndrome (GBS) treatment, leveraging unique molecules from PRONOXIS company. This project endeavors to introduce novel drug candidates, employing a groundbreaking immunological mechanism, into clinical trials for GBS. Neurix's contribution lies in providing human in vitro neural tissues to expedite drug development and assess the neurotoxicity of newly developed interventions, specifically Reactive Oxygen Species (ROS) Activators.
On the Horizon: Advancing Multiple Sclerosis Research
Multiple sclerosis (MS) poses a significant neurological disability challenge among young adults, arising from an autoimmune response against myelin and neurodegeneration. A dynamic consortium, comprising universities and companies spanning 11 European countries and the US, is determined to join forces and customize therapies tailored to individual MS patients within an ambitious 5-year timeframe. At Neurix, our mission is to forge ahead with a cutting-edge 3D human in vitro model, revolutionizing the testing of novel MS therapeutic interventions. Focused on the demands of the industry, our aim is to target neurorepair and myelin restoration, taking bold strides towards a brighter future for those affected by this complex neurological condition.
Alzheimer's Disease
Swiss-South Korean
collaboration
Unraveling Alzheimer's Disease: A Global Pursuit" Understanding the development of Alzheimer's disease (AD) challenges researchers and society, with aging populations in developed countries. Our Swiss-South Korean joint project, "Alzheimer's Kit&Screen," aims to develop a novel diagnostic kit and drug screening assays within 3 years. Utilizing newly identified biomarkers, we'll create human in vitro neural models of AD in 3D (AD mini-brains) to meet industry needs. Validating the drug screening potential of these models is our mission. Together, we revolutionize AD research.
CELESTE Chronic Septic Granulomatosis
Swiss-French Consortium
Through complementary expertise from French and Swiss partners, the CELESTE consortium strives to accelerate the development of new immunotherapeutics for Chronic Septic Granulomatosis disease. The innovative approach centers around modeling inflammatory disease through the establishment of cutting-edge in vitro screening tests based on patient-derived human induced pluripotent stem cells (iPSCs). Neurix plays a pivotal role by conducting a comprehensive quality control of iPSCs-derived human hematopoietic stem cells from patients, assessing their potential to differentiate into various blood cell types. This vital evaluation will be instrumental in testing new interventions and therapeutic applications that impact their differentiation potential.